Michel Clanet

9.7k total citations
78 papers, 3.1k citations indexed

About

Michel Clanet is a scholar working on Pathology and Forensic Medicine, Neurology and Molecular Biology. According to data from OpenAlex, Michel Clanet has authored 78 papers receiving a total of 3.1k indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Pathology and Forensic Medicine, 20 papers in Neurology and 13 papers in Molecular Biology. Recurrent topics in Michel Clanet's work include Multiple Sclerosis Research Studies (34 papers), Peripheral Neuropathies and Disorders (10 papers) and T-cell and B-cell Immunology (8 papers). Michel Clanet is often cited by papers focused on Multiple Sclerosis Research Studies (34 papers), Peripheral Neuropathies and Disorders (10 papers) and T-cell and B-cell Immunology (8 papers). Michel Clanet collaborates with scholars based in France, United States and Switzerland. Michel Clanet's co-authors include Ludwig Kappos, Gilles Edan, Sandra Vukusic, Jean Pelletier, Marc Debouverie, Thibault Moreau, Christine Lebrun‐Frénay, Bruno Brochet, Per Soelberg Sørensen and Reinhard Hohlfeld and has published in prestigious journals such as New England Journal of Medicine, PLoS ONE and Neurology.

In The Last Decade

Michel Clanet

75 papers receiving 3.0k citations

Peers

Countries citing papers authored by Michel Clanet

Since Specialization

Citations

This map shows the geographic impact of Michel Clanet's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michel Clanet with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michel Clanet more than expected).

Fields of papers citing papers by Michel Clanet

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michel Clanet. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michel Clanet. The network helps show where Michel Clanet may publish in the future.

Co-authorship network of co-authors of Michel Clanet

This figure shows the co-authorship network connecting the top 25 collaborators of Michel Clanet. A scholar is included among the top collaborators of Michel Clanet based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michel Clanet. Michel Clanet is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	MEsenchymal StEm cells for Multiple Sclerosis (MESEMS): a randomized, double blind, cross-over phase I/II clinical trial with autologous mesenchymal stem cells for the therapy of multiple sclerosis 2019 ·Trials ·(unknown), Antonio Uccelli, Alice Laroni, Lou Brundin, Michel Clanet, Óscar Fernández, Seyed Massood Nabavi, Paolo A. Muraro, Roberto S Oliveri, Ernst W. Radue, (unknown), Per Soelberg Sørensen, Maria Pia Sormani, Jens Wuerfel, Mario Alberto Battaglia, Mark S. Freedman	71
2	Vers une stratégie nationale de diagnostic des troubles cognitifs. Approche commune du Collège de médecine générale et des spécialistes des troubles neurocognitifs 2017 ·La Presse Médicale ·Pierre Krolak‐Salmon, Laurent Letrilliart, Mathieu Ceccaldi, Sandrine Andrieu, Olivier Guérin, Bruno Dubois, Bruno Brochet, Pierre Vandel, Claude Jeandel, (unknown), Michel Clanet, (unknown)	7
3	24-Month-Treatment with-MD1003 (High Doses of Biotin) in Progressive Multiple Sclerosis: Results of the MS-SPI Trial Extension Phase (S49.004) 2016 ·Neurology ·Ayman Tourbah, Christine Lebrun‐Frénay, Gilles Edan, Michel Clanet, Caroline Papeix, Sandra Vukusic, J. de Sèze, Marc Debouverie, Olivier Gout, Pierre Clavelou, Gilles Defer, David Laplaud, Thibault Moreau, Pierre Labauge, Bruno Brochet, Frédéric Sedel, Jean Pelletier	1
4	Excess Mortality in Patients with Multiple Sclerosis Starts at 20 Years from Clinical Onset: Data from a Large-Scale French Observational Study 2015 ·PLoS ONE ·Emmanuelle Leray, Sandra Vukusic, Marc Debouverie, Michel Clanet, Bruno Brochet, J. de Sèze, Hélène Zéphir, Gilles Defer, Christine Lebrun‐Frénay, Thibault Moreau, Pierre Clavelou, Jean Pelletier, Éric Berger, Philippe Cabre, Jean‐Philippe Camdessanché, (unknown), Christian Confavreux, Gilles Edan	50
5	Prospective Evaluation of Laparoscopic Assisted Cystectomy and Ileal Conduit in Advanced Multiple Sclerosis 2012 ·Urology ·J. Guillotreau, Jalesh N. Panicker, É. Castel-Lacanal, (unknown), M. Roumiguié, Bernard Malavaud, P. Marqué, Michel Clanet, P. Rischmann, X. Gamé	14
6	EFNS guidelines on diagnosis and management of neuromyelitis optica 2010 ·European Journal of Neurology ·Johann Sellner, M. Boggild, Michel Clanet, Rogier Q. Hintzen, Zsolt Illés, Xavier Montalbán, Renaud Du Pasquier, Chris H. Polman, Per Soelberg Sørensen, Bernhard Hemmer	330
7	Mast cell transcripts are increased within and outside multiple sclerosis lesions 2008 ·Journal of Neuroimmunology ·Nicolas Couturier, Jacques Zappulla, Valérie Lauwers‐Cancès, Emmanuelle Uro‐Coste, Marie‐Bernadette Delisle, Michel Clanet, Lisette Montagne, Paul van der Valk, Lars Bø, Roland Liblau	31
8	Thymic output and peripheral T lymphocyte subsets in relapsing–remitting multiple sclerosis patients treated or not by IFN-β 2008 ·Journal of Neuroimmunology ·Bénédicte Puissant‐Lubrano, (unknown), Peter Winterton, M. Abbal, Michel Clanet, Antoine Blancher	15
9	Mutations within the Programmed Cell Death 10 Gene Cause Cerebral Cavernous Malformations 2004 ·The American Journal of Human Genetics ·Françoise Bergametti, Christian Denier, Pierre Labauge, (unknown), S. Boetto, Michel Clanet, Philippe Coubes, Bernard Échenne, Rasha Ibrahim, B. Irthum, G Jacquet, M. Lonjon, J.-J. Moreau, J.‐P. Neau, Fabrice Parker, M Trémoulet, Elisabeth Tournier‐Lasserve	334
10	Intercellular adhesion molecule-1: a protective haplotype against multiple sclerosis 2003 ·Genes and Immunity ·Isabelle Cournu‐Rebeix, Emmanuelle Génin, Gaëtan Lesca, (unknown), Niall Tubridy, Eric Noé, Michel Clanet, Gilles Edan, Françoise Clerget‐Darpoux, G. Sémana, Bertrand Fontaine	27
11	Appearance of New Lesions in Two Nonfamilial Cerebral Cavernoma Patients 2001 ·European Neurology ·Pierre Labauge, L. Brunereau, Philippe Coubes, Michel Clanet, (unknown), Sophie Laberge, Claude Lévy	23
12	Guidelines for autologous blood and marrow stem cell transplantation in multiple sclerosis: a consensus report written on behalf of the European Group for Blood and Marrow Transplantation and the European Charcot Foundation 2000 ·Journal of Neurology ·(unknown), Gıancarlo Comı, Ludwig Kappos, Michel Clanet, George C. Ebers, Αthanasios Fassas, Franz Fazekas, Massimo Filippi, Hans‐Peter Hartung, Bernd Hertenstein, (unknown), Gianvito Martino, Alan Tyndall, F.G.A. van der Meché	59
13	MRI of intramedullary sarcoidosis: follow-up of a case 1997 ·Neuroradiology ·Emmanuelle Waubant, C. Manelfe, (unknown), I. Berry, Michel Clanet	13
14	Three highly polymorphic microsatellites at the human myelin oligodendrocyte glycoprotein locus, 100 kb telomeric to HLA-F 1995 ·Human Immunology ·Marie‐Paule Roth, (unknown), Nicolas Borot, Claire Amadou, Michel Clanet, Pierre Pontarotti, Hélène Coppin	30
15	Myelin oligodendrocyte glycoprotein (MOG) gene polymorphisms and multiple sclerosis: no evidence of disease association with MOG 1995 ·Journal of Neuroimmunology ·Marie‐Paule Roth, (unknown), Nicolas Borot, Pierre Pontarotti, Michel Clanet, Hélène Coppin	21
16	Tumor necrosis factor polymorphisms in multiple sclerosis: No additional association independent of HLA 1994 ·Journal of Neuroimmunology ·(unknown), Léonor Nogueira, Hélène Coppin, Michel Clanet, John Clayton, Anne Cambon‐Thomsen	51
17	Multiple Sclerosis Susceptibility. Population and Twin Study of Polymorphisms in the T-Cell Receptor β and γ Genes Region 1993 ·Autoimmunity ·Laurence Briant, (unknown), John L. Clayton, Michael McDermott, Michel Clanet, Anne Cambon‐Thomsen, (unknown)	9
18	Viral antibody titers, immunogenetic markers, and their interrelations in multiple sclerosis patients and controls 1991 ·Human Immunology ·Annick Alpérovitch, Claudine Berr, Anne Cambon‐Thomsen, J Puel, (unknown), J. B. Ruidavets, Michel Clanet	7
19	Human monoclonal autoantibodies produced by hybridomas derived from lymphocytes of multiple sclerosis patients 1989 ·Research in Immunology ·Antoine Blancher, F Oksman, Peggy Lymberi, Patrick Calvas, Anne Cambon‐Thomsen, Michel Clanet, J Ducos	3
20	CALCIUM ANTAGONISTS AND THE VESTIBULAR SYSTEM: A CRITICAL REVIEW OF FLUNARIZINE AS AN ANTIVERTIGO DRUG 1989 ·Fundamental and Clinical Pharmacology ·Olivier Rascol, Michel Clanet, Jean‐Louis Montastruc	9

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact